Literature DB >> 10675486

Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines.

M Yoshinouchi1, A Hongo, N Takamoto, Y Ono, S Nagao, Y Miyagi, T Kudo, J Kodama.   

Abstract

To determine whether alterations of the CDKN2/p16 might be involved in HPV-positive cervical cancers, we examined for alterations of this gene and function of the protein p16 to interact with CDK4 in 5 cervical cancer cell lines. No alteration of this gene was detected. Proteins for p16 and CDK4 were normally expressed and function of p16 to interact with CDK4 was not abrogated in these cell lines. These cell lines were human papillomavirus (HPV)-positive and carried wild-type p53. These findings suggest that phosphorylation of pRb by CDK4 is not critical in the carcinogenesis or in the establishment of HPV-positive cervical cancer cell lines, since HPV E6 or E7 viral-transforming proteins inactivate p53 and pRb tumor suppressor protein function, resulting in deregulated progression of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675486     DOI: 10.3892/ijo.16.3.537

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.

Authors:  N Murphy; M Ring; C C B B Heffron; B King; A G Killalea; C Hughes; C M Martin; E McGuinness; O Sheils; J J O'Leary
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

2.  p16 expression in squamous lesions of the female genital tract.

Authors:  Mary M Finegan; Aaron C Han; Mitchell I Edelson; Norman G Rosenblum
Journal:  J Mol Histol       Date:  2004-02       Impact factor: 2.611

Review 3.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

4.  p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem.

Authors:  N Murphy; C C B B Heffron; B King; U G Ganuguapati; M Ring; E McGuinness; O Sheils; J J O'Leary
Journal:  Virchows Arch       Date:  2004-09-18       Impact factor: 4.064

5.  Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel.

Authors:  Janani Ramesh; Rejani Chalikkaran Thilakan; Raja Mohan Gopalakrishnan; Singaravel Vijayapoopathi; Arianna Dorschel; Bhuvarahamurthy Venugopal
Journal:  Genes (Basel)       Date:  2022-06-24       Impact factor: 4.141

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.